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Background: The G455A fibrinogen polymorphism is associated with the risk of coronary artery disease. However, it remains unknown whether it 
affects the prothrombotic profile of patients with hypertension (HT). We aimed to examine the impact of this polymorphism on fibrinogen, D-dimers, 
factor V (fV) and factor X (fX) levels in hypertensive patients.
Methods: The study population consisted of 457 HT and 224 non HT. The G455A polymorphism was determined by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) technique, while circulating levels of fibrinogen were measured by the von Clauss method. 
D-dimers levels, fV and fX levels were measured by standard coagulometry techniques.
Results: Genotype distribution for non HT and HT was GG: 50.9%, GA: 41.8%, AA: 9.7% and GG: 51.5%, GA: 37.6%, AA: 10.9% respectively. There 
was no significant difference in fibrinogen levels (mg/dl) between 455AA homozygotes and 455G allele carriers in non HT patients (448.3±34.6 vs 
395.4±9.9, p=NS). Importantly, 455AA genotype presented with much more elevated levels of fibrinogen compared to the GG+GA in HT patients 
(535.4±25.3 vs 414.2±8.0, p<0.001). Moreover, HT 455AA homozygotes had significantly increased D-dimers levels (μg/l) compared to 455G allele 
carriers (640.3±83.6 vs 485.5±27.2, p<0.05). No difference was observed for non HT regarding D-dimers between the 455AA genotype and GG+GA 
(477.6±74. vs 450.8±40.7, p=NS). Interestingly, 455AA genotype presented with higher fV(%) and fX(%) levels compared to GG+GA in HT patients 
(133.6±5.8 vs 117.8±3.3, p<0.05, for fV) and (101.9±4.6 vs 92.2±2.4, p<0.05, for fX). However, no difference was observed in fV and fX levels 
between 455AA and GG+GA in non HT (105.8±11.6 vs 118.7±4.4, p=NS for fV) and (95.8±8.0 vs 119.4±29.1, p=NS for fX).
Conclusions: The G455A fibrinogen genetic polymorphism has a remarkable impact on prothrombotic profile of patients with hypertension, 
by affecting fibrinogen, D-dimers, factor V and factor X levels. These findings provide evidence that this polymorphism modifies further the 
atherosclerotic effects of hypertension via alterations in the coagulation cascade.
